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Background: Small cell lung cancer (SCLC) is usually classiﬁed us-
ing the limited and extensive deﬁnition. The Tumor Node Metastasis 
(TNM) classiﬁcation should also be applicable to SCLC but it has only 
been reported in small surgical series. The current analysis looks to the 
impact of the TNM systems on the clinical staging of SCLC and of the 
new International Association for the Study of Lung Cancer (IASLC) 
proposals.
Methods: Using the IASLC database, survival analyses were performed 
for clinically staged patients. Prognostic groups were compared and the 
new IASLC TNM proposals were applied to this population and to the 
Surveillance, Epidemiology and end Results (SEER) database.
Results: The IASLC database contained 12,620 eligible cases of small 
cell histology. TNM staging was available for 8088 patients. Survival 
was directly correlated to both T and N stage. Differences were more 
pronounced in patients without mediastinal or supraclavicular nodal 
involvement. Clinical Union Internationale Contre Le Cancer (UICC) 
stage grouping also differentiates survival except between 1A and 1B. 
Patients with pleural effusion regardless of the cytology have an inter-
mediate prognosis between limited and extensive disease. The IASLC 
proposals for the 7th edition of the TNM classiﬁcation also apply to this 
series of SCLC and to the SEER database.
Conclusion: TNM staging is recommended for SCLC and stratiﬁca-
tions by stage I-III should be incorporate in clinical trials of early stage 
disease. Further studies are needed to clarify the impact of pleural effu-
sion and the extent of N3 disease.
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Lung cancer frequently involves the skeleton with 30 - 40% of lung 
cancer patients developing bone metastasis. Tumors can have multiple 
deleterious effects on the skeleton including hypercalcemia, bone 
metastasis and treatment induced bone loss. Over 350,000 people per 
year in the United States die with bone metastases, and once tumors 
metastasize to bone, the patients are incurable. Tumor involvement of 
the skeleton can result in severe bone pain, pathologic fractures, and 
life threatening hypercalcemia. In addition, lung cancer can produce cy-
tokines and growth factors such as parathyroid related protein (PTHrP), 
which can act as a hormone and induce increased bone resorption and 
hypercalcemia at sites distant from the tumor. When tumors metastasize 
to the skeleton, they can form either blastic metastasis, in which new 
bone is formed rapidly but the bone is of poor quality, or lytic bone me-
tastasis, where bone is destroyed. In lung cancer, lytic bone metastases 
are the most common type of metastases. When lung cancer homes to 
the bone, it induces bone destruction, and this bone destructive process 
releases and activates growth factors stored in the bone, to stimulate the 
growth of the tumors. Thus, a vicious cycle is set up where the tumor 
growth induces bone destruction and the bone destructive process 
increases the growth of the tumor. Further, when tumors home to the 
bone, adhesive interactions between tumor cells and marrow stromal 
cells increase angiogenesis and make the tumors more chemoresistant. 
Tumors ursurp the normal bone remodeling process and increase osteo-
clast activity by upregulating the RANK/RANK Ligand/osteoproteger-
in signaling pathway that plays a critical role in normal bone remodel-
ing. Once in the bone marrow microenvironment, lung cancer cells 
secrete factors that increase expression of RANK Ligand, which drives 
osteoclast formation and decreases expression of the RANK Ligand 
decoy receptor, osteoprotegerin (OPG) which blocks normal osteoclast 
formation. This shifts the normal balance between RANK Ligand and 
osteoprotegerin to favor osteoclastogenesis. In addition, in lytic bone 
metastases, osteoblast differentiation is suppressed, further exacerbat-
ing the bone destructive process. Importantly, when tumor cells interact 
with stromal cells, a multiplicity of growth factors that are derived from 
marrow stromal cells and immature osteoblast are also released that 
affect bone metastasis. These factors can induce tumor cell chemotaxis, 
increase adhesion of tumor cells to stromal cells, induce tumor growth 
as well as induce osteoblast and osteoclast differentiation. Using animal 
models of bone metastases, in which tumor cells are injected into the 
left ventrical of mice, groups such as Iguchi and coworkers (Cancer 
Res. 1996,56:4040-3) have shown that bone cancer metastasis from 
lung cancer produce high levels of PTHrP. PTHrP, like parathyroid 
hormone, binds the PTH receptor. PTHrP is released by the lung cancer 
cells, suppresses production of OPG and increases RANK Ligand 
expression on stromal cells. This increase in RANK Ligand stimulates 
osteoclastic bone destruction and increases release of calcium and 
growth factors from bone to stimulate tumor growth, exacerbating a 
vicious cycle between tumor growth and the bone destructive process. 
Miki and coworkers (Int. J. Cancer 2004, 108:511-5) have shown that 
an antibody PTHrP can block bone metastasis in animal models of 
lung cancer. Furthermore, increased PTHrP production by lung cancer 
cells may explain the severe cachexia seen in patients with lung cancer. 
PTHrP can induce cachexia in animal models of bone metastasis, and 
a humanized PTHrP antibody has been developed which blocks the ef-
fects of PTHrP and decreases weight loss in lung cancer models in mice 
(Iguchi et al., J. Bone Mineral Res. 2006, 24:16-19). In addition to bone 
destroying osteolytic metastases, osteoblastic metastases may rarely 
occur in lung cancer. Tumor cells can release factors which stimulate 
new bone formation, but even in osteoblast metastasis, there is ongoing 
bone destruction. Thus, new insights into the pathophysiology of lung 
cancer metastasis have identiﬁed several new therapeutic targets for 
treating bone metastases in lung cancer patients. These include RANK 
Ligand and PTHrP where a neutralizing antibody to RANK Ligand is 
in clinical trial in patients with breast cancer, myeloma, and other bone 
metastases and an antibody to PTHrP. 
